Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HST-NEETs and ASCT for HIV Associated Lymphoma
NCT04975698Phase 2Completed
- Sponsor
- Catherine Bollard
- Start
- Oct 2021
- Primary completion
- Nov 2025
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HST-NEETs in lymphoma, sponsored by Catherine Bollard. Primary endpoints: Proportion of participants treated with HST-NEETs within 1 week of ASCT and Efficacy of HST-NEETs in reducing the HIV intact proviral at 6 months. Started Oct 2021; status: completed.
02
Drugs
HST-NEETs
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT04975698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975698.